WELCOME TO THE LEEDS SCLERODERMA RESEARCH PROGRAM
Overview of Our Research
The Scleroderma Research Program in Leeds is a patient-centred program which includes basic, translational and clinical research on Raynaud's and Scleroderma or Systemic Sclerosis. Founded in 2009 by Dr Del Galdo, the program aims to improve our understanding of the cellular and molecular events leading to Scleroderma, and to improve early diagnosis and clinical management of the disease in order to minimise the burden of Scleroderma and improve the quality of life of our patients. From research into the basic mechanisms of autoimmunity and fibrosis through to diagnostic and intervention trials, individually and as a team we are committed to making a difference for our patients by implementing precision medicine-based prevention approaches for Scleroderma.
 |  |  |
|---|---|---|
 |  |  |
 |
WHAT IS SCLERODERMA ?
Scleroderma is a rare autoimmune disease causing a highly variable level of tissue and vascular fibrosis in the skin and internal organs. For more information on this condition please visit the website linked below.
